Abstract | PURPOSE: Materials and Methods: RESULTS: Among a total of 643 patients randomized to eflapegrastim (n=314) or pegfilgrastim (n=329), 54 Asians (29 to eflapegrastim and 25 to pegfilgrastim) including 28 Koreans (14 to both eflapegrastim and pegfilgrastim) were enrolled. The primary endpoint, DSN in cycle 1 in the eflapegrastim arm was non-inferior to the pegfilgrastim arm in Koreans and Asians. The DSN difference between the eflapegrastim and pegfilgrastim arms was consistent across populations: -0.120 days (95% confidence interval [CI], -0.227 to -0.016), -0.288 (95% CI, -0.714 to 0.143), and -0.267 (95% CI, -0.697 to 0.110) for pooled population, Koreans and Asians, respectively. There were few treatment-related adverse events that caused discontinuation of eflapegrastim (1.9%) or pegfilgrastim (1.5%) in total and no notable trends or differences across patient populations. CONCLUSION: This study may suggest that eflapegrastim showed non-inferior efficacy and similar safety compared to pegfilgrastim in Koreans and Asians, consistently with those of pooled population.
|
Authors | Yong Wha Moon, Seung Ki Kim, Keun Seok Lee, Moon Hee Lee, Yeon Hee Park, Kyong Hwa Park, Gun Min Kim, Seungtaek Lim, Seung Ah Lee, Jae Duk Choi, Eunhye Baek, Hyesun Han, Seungjae Baek, Seock-Ah Im |
Journal | Cancer research and treatment
(Cancer Res Treat)
Vol. 55
Issue 3
Pg. 766-777
(Jul 2023)
ISSN: 2005-9256 [Electronic] Korea (South) |
PMID | 36701846
(Publication Type: Equivalence Trial, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- eflapegrastim
- Filgrastim
- Granulocyte Colony-Stimulating Factor
- pegfilgrastim
- Polyethylene Glycols
|
Topics |
- Female
- Humans
- Antineoplastic Agents
(adverse effects)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects)
- Breast Neoplasms
(drug therapy)
- Filgrastim
(therapeutic use)
- Granulocyte Colony-Stimulating Factor
(therapeutic use)
- Neutropenia
(chemically induced, drug therapy)
- Polyethylene Glycols
- Republic of Korea
- East Asian People
|